CSF3 and neoplasm: The TL trial, however, was a double-blind trial with 187 patients enrolled in four treatment arms: TLPLDC (n = 47), TLPDC + G (tumor lysate, particle-loaded, dendritic cell harvested with granulocyte-colony stimulating factor) (n = 56), TLPO (n = 43), and placebo (n = 41).